{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"data_sharing_plan":["IPD Sharing (as of March 2023): No"],"condition":["Carcinoma","Triple Negative Breast Neoplasms","GastroEsophageal Cancer","Colorectal Cancer Metastatic","Non Small Cell Lung Cancer","Colorectal Neoplasms","Carcinoma, Renal Cell","Triple Negative Breast Cancer","Bladder Cancer","Renal Cell Carcinoma","Breast Neoplasms","MSI-H"],"disease":["Carcinoma","Triple Negative Breast Neoplasms","Non Small Cell Lung Cancer","Carcinoma, Renal Cell","Colorectal Cancer Metastatic","Colorectal Neoplasms","Triple Negative Breast Cancer","Bladder Cancer","Gastroesophageal Cancer","Renal Cell Carcinoma","Breast Neoplasms","Msi-h"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2292184"],"location":["Canada","United States"],"study_start_month":["12"],"keyword":["Pembrolizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors","description":"This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors","dates":{"creation":"2018-12-15"},"accession":"2292184","cross_references":{"ClinicalTrials___gov":["NCT03775850"]}}